By Abhishek Singhh | Published on abhishekschauhan.com
As seen on: ANI News · Outlook Business · The Print · News X · The Tribune · MSN · The Daily Guardian
Your father had a heart attack at 54. His elder brother at 51. You are 47, your cholesterol is “borderline,” your blood pressure was 138/88 at the last checkup. Your doctor said keep an eye on it.
You are keeping an eye on it. But you don’t fully understand what you are looking at.
This is the gap that kills people.
The Five-Year Gap That Should Define Public Health Policy in India
Indians develop cardiovascular disease 5–10 years earlier than any other population on the planet.
The mean age for first presentation of acute myocardial infarction — a heart attack — in Indians is 53 years. The global average is 58–60. That is not a minor statistical footnote. That is five years of life, five years of productive work, five years with your family — gone before the global average person has even had their first cardiac event.
The NSO 2025 survey, one of the most comprehensive health assessments India has conducted, found that cardiovascular disease has nearly tripled in seven years. In 2017–18, there were 1,333 cardiovascular cases per one lakh population. By 2025, that figure had risen to 3,891 per one lakh. A 192% increase in less than a decade.
The same survey found that 13.9% of people in the 45–59 age group were hospitalised due to cardiovascular disease. Among those over 60, the figure rose to 18.2%.
India accounts for one-fifth of all cardiovascular deaths globally. A country with one-sixth of the world’s population is absorbing 20% of its cardiac mortality.
This is not a background statistic. If you are between 45 and 65, Indian, urban, and reading this — this data is about you.
Why the Indian Heart Is Structurally More Vulnerable
The earlier onset of cardiovascular disease in Indians is not purely a lifestyle failure. It is, in part, a biological reality that the medical establishment has understood for decades but that public health communication has almost entirely failed to translate into individual awareness.
Lipoprotein(a) — the risk factor 90% of Indians have never heard of.
Lp(a) — pronounced “L-P-little-a” — is a modified form of LDL cholesterol that is independently associated with cardiovascular disease, particularly in South Asians. Unlike standard LDL, Lp(a) levels are almost entirely genetically determined. Diet and exercise do not move them meaningfully. They are elevated in a disproportionate percentage of the Indian population compared to Western populations — some studies suggest South Asians have among the highest Lp(a) levels globally.
Elevated Lp(a) is not included in a standard lipid panel in India. Most people have never been tested for it. They get their total cholesterol, LDL, HDL, and triglycerides — and walk away thinking they know their cardiac risk. They may not. A person with normal LDL and elevated Lp(a) carries significantly higher cardiac risk than their standard blood report suggests.
This is one reason Indians have heart attacks at 53 while thinking their cholesterol was fine.
Visceral fat and the lean-but-risky body type.
As I wrote in my article on pre-diabetes, Indians store proportionally more visceral fat — the dangerous fat packed around internal organs — relative to subcutaneous fat, even at normal BMI. Visceral fat is metabolically active in the worst possible way. It produces inflammatory molecules that directly damage arterial walls, promote clot formation, and drive the insulin resistance that accelerates cardiovascular disease.
The Indian who looks lean, has a normal BMI, and feels generally healthy can be carrying dangerous levels of visceral fat that no bathroom scale and no standard blood test reveals. A waist circumference above 90cm in men and 80cm in women is a better proxy for visceral fat risk in Indians than BMI — but almost nobody measures it or discusses it at a routine checkup.
The inflammation chain nobody connects.
Cardiovascular disease is not fundamentally a cholesterol problem. It is fundamentally an inflammation problem. Cholesterol — specifically oxidised LDL — deposits in arterial walls in the presence of chronic inflammation. Remove the inflammation and the same LDL level causes significantly less arterial damage. Sustain the inflammation and even moderate LDL levels become dangerous.
What drives chronic inflammation in urban India? The same cluster of factors I have documented across every article in this series: chronic cortisol dysregulation from burnout and overwork, gut microbiome disruption from a processed-food urban diet, vitamin D deficiency, magnesium deficiency, chronic sleep deprivation, and insulin resistance from high-glycaemic diets.
Every condition in this series is a separate thread. At the cardiovascular level, they converge. The 52-year-old Indian man who has been burned out for five years, sleeps poorly, has pre-diabetes, is vitamin D deficient, and has a gut microbiome that looks nothing like it should — is not experiencing five separate health problems. He is experiencing one systemic inflammatory state that is expressing itself across five organ systems simultaneously. The heart attack at 53 is not a sudden event. It is the downstream conclusion of a decade of unaddressed biology.
The Silent Killer Hiding Inside “Normal” Blood Reports
One in five heart attacks globally is silent — the damage is done with no classic symptoms. No dramatic chest pain. No left-arm numbness. The patient had “indigestion” that week or felt more tired than usual. The heart attack is discovered incidentally on an ECG or not at all until the next, larger event.
In India, where cardiac awareness is low and routine cardiac screening is even lower, the silent heart attack rate is likely significantly higher than the global one-in-five figure.
The standard blood tests most Indians do annually — fasting glucose, lipid panel, liver function, kidney function, CBC — tell you almost nothing about cardiovascular risk in isolation. The markers that actually predict cardiac events in a 45–65-year-old Indian are largely not being ordered routinely:
hs-CRP (high-sensitivity C-reactive protein) — the most widely validated marker of systemic inflammation and cardiovascular risk. A simple blood test. Costs ₹400–800 at most labs. Not in a standard health package. Not discussed at most GP consultations.
Lp(a) — the genetically elevated particle discussed above. Tested once in a lifetime is sufficient for most people since levels are stable. Costs ₹800–1,500. Almost nobody orders it.
HbA1c and fasting insulin — together they reveal insulin resistance far earlier than fasting glucose alone. The person who has normal fasting glucose but elevated fasting insulin is already insulin resistant — and insulin resistance is one of the most potent drivers of cardiovascular disease. Not in a standard panel.
Homocysteine — elevated homocysteine damages arterial walls directly and is particularly relevant for Indians because B12 deficiency, which drives elevated homocysteine, is endemic in India’s largely vegetarian population. B12 deficiency + elevated homocysteine is a combination that significantly elevates cardiovascular risk in Indian vegetarians and goes almost entirely undetected.
ApoB — a better predictor of cardiovascular risk than LDL alone, particularly in the metabolic syndrome pattern common in urban Indians. Increasingly recommended by cardiologists. Rarely ordered by general practitioners.
None of this is obscure. All of it is available at standard diagnostic labs across India. The information exists. The system is not connecting it to the patient standing in front of it.
What the Supplement Industry Sells vs. What the Evidence Supports
The Indian cardiovascular supplement market is one of the fastest growing categories — omega-3, CoQ10, plant sterols, antioxidant blends, red yeast rice. Amazon India sees search surges for these products every time a high-profile cardiac event reaches the news cycle.
Most of what is being sold is based on real evidence. Most of it is being sold badly.
Omega-3 fatty acids have among the most robust evidence bases in cardiovascular medicine. A 2022 umbrella review of 884 randomised controlled trials found omega-3 supplementation reduced cardiovascular mortality, heart attack risk, and other cardiac events. This is not marginal evidence. It is among the most replicated findings in nutritional cardiology. The caveat: dose and form matter enormously. Most Indian omega-3 supplements contain 300mg of EPA+DHA per capsule — well below the 1,000–2,000mg daily dose used in the trials demonstrating cardiovascular benefit. The label says omega-3. The dose is a fraction of what the evidence used.
CoQ10 (Coenzyme Q10) is produced naturally in the body and plays a central role in mitochondrial energy production — including in cardiac muscle cells, which have among the highest energy demands of any tissue. Production declines with age, starting meaningfully in the 40s. A 2024 systematic review and meta-analysis confirmed CoQ10 supplementation improves mitochondrial function and systolic function in patients with cardiovascular disease. Critically, anyone taking a statin — and India’s statin prescription rate is high — should be aware that statins deplete CoQ10 production. The cardiologist who prescribes the statin almost never mentions the CoQ10 depletion. The patient takes the statin, feels more fatigued, and attributes it to aging.
Curcumin — the active compound in turmeric — has evidence for anti-inflammatory effects relevant to cardiovascular risk, particularly for reducing hs-CRP and oxidised LDL. The problem: standard turmeric powder and most curcumin capsules have very low bioavailability. Curcumin is poorly absorbed without piperine or in a liposomal or phospholipid complex form. The dal and sabzi your mother made with turmeric every day provided a meaningful cumulative dose. The ₹300 curcumin capsule without a bioavailability enhancer may not.
What does not work despite the marketing: Beta-carotene supplements are associated with increased cardiovascular mortality in smokers. Vitamin E supplementation at high doses has no benefit and potential harm. Antioxidant megadosing with vitamins C and E has consistently failed to demonstrate cardiovascular benefit in clinical trials despite decades of theoretical promise. The supplement industry has been slower to update its marketing than the science has been to produce the negative findings.
The Conversation Between You and Your Doctor That Needs to Change
Most Indians between 45 and 65 who are at cardiac risk are not having the right conversation with their doctor. Not because the doctor is incompetent, but because the system is structured around disease management, not risk identification. The 10-minute consultation, the standard panel, the “come back if symptoms worsen” — this is not a cardiovascular prevention system. It is a cardiovascular treatment system that starts when the disease is already advanced.
The questions you should be asking at your next checkup, if you are in the 45–65 age group and have not had them addressed:
What is my Lp(a)? If you have never been tested, ask for it once. It does not change. If it is elevated, your cardiovascular management needs to account for it regardless of your other numbers.
What is my hs-CRP? This tells you whether you have systemic inflammation driving arterial damage right now. If it is above 3 mg/L, you have elevated cardiovascular risk independent of your cholesterol.
What is my fasting insulin, not just fasting glucose? Insulin resistance precedes blood sugar elevation by years. The fasting insulin level tells you what the fasting glucose is concealing.
What is my homocysteine? If you are a vegetarian or eat limited animal protein, B12 deficiency is likely. Elevated homocysteine from B12 deficiency is directly cardiotoxic and entirely addressable with supplementation.
What is my waist circumference in centimetres? Not weight. Not BMI. Waist circumference. Above 90cm for Indian men and 80cm for Indian women is a risk marker regardless of what the rest of the numbers say.
These five questions cost nothing to ask. The tests together cost less than ₹3,000. The information they provide is orders of magnitude more useful than knowing your total cholesterol.
The Upstream Problem This Series Has Been Building Toward
Every article I have written in this series has been about a different piece of the same problem. Supplements designed for labels rather than biology. Sleep that does not restore. Vitamin D deficiency in a sunny country. Pre-diabetes hitting professionals in their 30s. Burnout rates three times the global average. Each of these is a separate clinical conversation. At the cardiovascular level, they become one.
The chronic inflammation that develops from years of cortisol dysregulation, gut microbiome damage, vitamin D deficiency, insulin resistance, and poor sleep is the exact mechanism by which cardiovascular disease develops and accelerates. Fix any one of these and you reduce cardiovascular risk. Fix several of them and you meaningfully change the trajectory of what happens at 53.
The 45-year-old reading this who addresses their burnout, gets their vitamin D status corrected, manages their blood sugar trajectory, and improves their sleep quality is not just feeling better in the short term. They are changing the biological environment in which their arteries age over the next decade.
Cardiovascular disease is not an event. It is a process. It begins silently, accelerates invisibly, and announces itself at 53 as if it came out of nowhere.
It did not come out of nowhere. It came out of the previous decade.
The decade that matters most is the one you are in right now.
This is part of an ongoing series on what India’s wellness industry gets wrong — and what the evidence actually says. Read the rest of the series: Why Your Supplement Is Lying to You · Indians Are Sleeping More Than Ever. So Why Are They Waking Up Exhausted? · India Has More Sunshine Than Almost Any Country on Earth. So Why Is Half the Population Vitamin D Deficient? · You Are 32 Years Old, Relatively Fit, and Pre-Diabetic · India Is the Most Burned-Out Country on Earth
Abhishek Singhh is the founder of Just What Works™ (Elara Biosciences), JeevRasa, The FarmPURE, ReEarthy, and SuppleFoods — five wellness brands built on one shared belief: the wellness industry has a honesty problem. He writes on supplement science, D2C brand building in India, and Ayurveda as a serious industry.
Follow on LinkedIn
Abhishek Singh is the founder of Just What Works and a passionate entrepreneur in the nutraceutical space. Through his brand and writing, he shares practical business strategies, wellness insights, and real-world lessons from his own startup journey. His work helps readers cut through noise and focus on building businesses — and lives — that truly work.